标题:Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
作者:Chen, Fengquan; Liu, Chunxi; Zhang, Jian; Xu, Wenfang; Zhang, Yingjie
作者机构:[Chen, Fengquan; Xu, Wenfang; Zhang, Yingjie] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, 44 West Culture Rd, Jinan 250012, Shandong, Peoples R 更多
通讯作者:Xu, WF;Zhang, YJ
通讯作者地址:[Xu, WF; Zhang, YJ]Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China.
来源:ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
出版年:2018
卷:18
期:9
页码:1241-1251
DOI:10.2174/1871521409666170412123500
关键词:Cyclin-Dependent Kinases (CDKs); palbociclib; monotherapy; combined; therapy; anti-cancer; cell cycle arrest
摘要:The Cyclin-Dependent Kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents. The CDK inhibitors can effectively suppress the excessive proliferation of tumor cells by inducing cell cycle arrest. In recent years, a large number of CDK inhibitors have entered pre-clinical and/or clinical trials. Among these compounds, the selective CDK4/6 inhibitor Palbociclib has been approved by FDA for breast cancer treatment. Moreover, Palbociclib demonstrated promising antitumor potential as monotherapy or combined therapy in numerous clinical trials. Herein, we provide a brief review focused on the recent progress of clinical studies about Palbociclib.
收录类别:SCOPUS;SCIE
WOS核心被引频次:1
Scopus被引频次:1
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053009801&doi=10.2174%2f1871521409666170412123500&partnerID=40&md5=c61a5691d0ec9c1432dc545493adfb05
TOP